VILDAGLIPTIN 100mg. IP

A dipeptidyl peptidase-4 (DPP-4) inhibitor that treats patients with type 2 diabetes mellitus. (Sheridan Henness, 2006) Improves glycaemic control in type 2 diabetes by inhibiting DPP-4. (Sheridan Henness, 2006) A well-tolerated and efficacious antidiabetic drug in reducing glycosylated hemoglobin, fasting plasma glucose, and postprandial glucose levels. (Prato, 2007) Enhances beta-cell functionality in diabetic patients by boosting insulin secretion. (A Mari, 2005) A safe therapeutic option for managing patients with type 2 diabetes mellitus. (Chantal Mathieu, 2017) Improves the sensitivity and responsiveness of pancreatic α-cells and β-cells to glucose. (Dejager, 2013) An efficacious and safe treatment both as monotherapy and in combination with metformin. (Matthias Blüher, 2012) Effectively improves blood sugar control in a broad range of T2DM patients, including those with impaired glucose tolerance and advanced disease requiring insulin therapy. (Degrande, 2008) An effective and well-tolerated for patients with type 2 diabetes mellitus who have inadequate control with metformin monotherapy. (M Goodman, 2009) A potentially beneficial treatment option for patients with type 2 diabetes due to its inhibition of DPP-4, leading to increased levels of incretin hormones. (Yan-Ling He, 2007)